AMENDMENT NO. 1 TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENTVeto Cell Production and Clinical Trial Program Agreement • May 20th, 2019 • Cell Source, Inc. • Pharmaceutical preparations
Contract Type FiledMay 20th, 2019 Company IndustryThis Amendment No. 1 to the Veto Cell Production and Clinical Trial Program Agreement (“Amendment”) is made and entered into as of April 4, 2019 by and between Cell Source Limited (“Cell Source”) and The University of Texas M.D. Anderson Cancer Center (“MD Anderson”), a member institution of The University of Texas System (“System”).